Food Allergy Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Food Allergy Treatment Market is projected to expand from USD 7.15 Billion in 2025 to USD 11.53 Billion by 2031, achieving a CAGR of 8.29%. This sector encompasses the development and commercialization of pharmaceutical interventions and immunotherapies aimed at desensitizing the immune system or managing acute anaphylactic reactions triggered by specific dietary proteins. The primary force driving this growth is the rapidly rising global prevalence of sensitization to allergens like peanuts, milk, and eggs, which creates a critical demand for effective clinical management strategies beyond simple avoidance. Furthermore, the recent regulatory approval and launch of biologic agents that facilitate desensitization are significantly boosting the sector by offering healthcare providers new mechanisms to reduce the severity of allergic reactions.

However, the market confronts a major obstacle regarding the high cost of new therapies and a complicated reimbursement environment that frequently limits broad patient access. These financial hurdles often obstruct the equitable availability of life-altering treatments across various demographic groups. As reported by Food Allergy Research & Education in 2024, approximately 33 million individuals in the United States were living with life-threatening food allergies, underscoring a massive addressable market that remains partially restricted by affordability challenges.

Market Drivers

The rapid adoption of innovative immunotherapies and biologics is fundamentally transforming the Global Food Allergy Treatment Market, shifting clinical care beyond mere avoidance tactics. This evolution is underpinned by recent regulatory achievements that provide medical professionals with the first pharmaceutical options capable of reducing reaction severity across multiple allergens simultaneously.

For instance, Genentech reported in a February 2024 press release titled 'FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies' that clinical trials showed 68% of patients treated with Xolair for 16 to 20 weeks could tolerate at least 600 mg of peanut protein without moderate to severe symptoms, compared to only 5% of the placebo group. Such strong efficacy data encourages the swift integration of biologic agents into standard treatment protocols, directly broadening the addressable market for therapeutic interventions.

Simultaneously, the increasing global prevalence of severe food allergies in both children and adults is heightening the urgency for these disease-modifying solutions. The market's trajectory is heavily influenced by a patient population facing life-threatening risks, resulting in a critical unmet need for treatments that prevent anaphylaxis. Data from the Centers for Disease Control and Prevention in 2024 indicates that at least 40% of children with food allergies have been treated in the emergency department for reactions, highlighting the condition's severity. This significant disease burden drives substantial commercial activity and development spending; as noted by DBV Technologies in their 'Third Quarter 2024 Financial Results' from November 2024, operating expenses reached $96.4 million for the first nine months of the year, primarily to support the advancement of pivotal clinical trials.

Market Challenges

The commercial expansion of the Global Food Allergy Treatment Market is significantly hindered by the high cost of novel therapies and a complex reimbursement landscape. Although pharmaceutical advancements provide new desensitization mechanisms, the extensive research and development investments required for these biologics compel manufacturers to set premium list prices. Consequently, health insurers often categorize these treatments as non-essential or place them in tiers with high out-of-pocket costs, creating a financial barrier that restricts patient adoption. This gap between clinical availability and economic accessibility limits the serviceable addressable market, as only a fraction of the diagnosed population can afford continuous therapy, thereby stalling revenue growth for manufacturers.

This financial friction is further exacerbated by the existing economic burden placed on families managing these conditions. The Asthma and Allergy Foundation of America estimated in 2025 that the inflation-adjusted annual economic cost of caring for children with food allergies was approximately $34 billion. This substantial figure illustrates the heavy financial load already borne by households, making the additional expense of high-priced pharmaceutical interventions untenable for many. As a result, the market struggles to convert high clinical demand into sustained therapeutic adoption.

Market Trends

The emergency response segment is undergoing a significant transition from traditional auto-injectors to needle-free alternatives, specifically with the commercialization of intranasal epinephrine sprays. This trend directly targets critical barriers such as needle phobia and device bulkiness, which have historically delayed the administration of life-saving medication during anaphylactic events. Manufacturers are currently utilizing aggressive pricing strategies and partnership models to ensure these novel delivery systems rapidly penetrate the market and become accessible to a broad patient base. For example, according to a September 2024 press release by GoodRx titled 'GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy,' a strategic partnership was established to allow consumers to access a pack of two single-use neffy devices for $199 at over 70,000 pharmacies, significantly lowering the financial hurdle for this new technology.

At the same time, the market is seeing a surge in the development of Epicutaneous Immunotherapy (EPIT) platforms, which deliver micro-doses of allergens through the skin to induce tolerance with fewer systemic side effects than oral routes. This non-invasive approach is rapidly moving through late-stage clinical pipelines, aiming to provide a safer desensitization option for pediatric patients who may not tolerate the gastrointestinal side effects associated with oral immunotherapy. Reflecting the substantial scale of this clinical development, DBV Technologies announced in an October 2024 press release titled 'DBV Announces Positive Regulatory Updates for the Viaskin Peanut Patch' that the company successfully enrolled a total of 654 subjects in the Phase 3 VITESSE efficacy trial to evaluate the modified peanut patch in children.

Key Players Profiled in the Food Allergy Treatment Market

• Aimmune Therapeutics
• DBV Technologies
• Regeneron
• Sanofi
• Nestle Health Science
• Novartis
• Immune Design
• TanGenix
• Allergen Labs
• FARE-associated Innovators

Report Scope

In this report, the Global Food Allergy Treatment Market has been segmented into the following categories:

Food Allergy Treatment Market, by Allergen Type:

• Dairy Products
• Poultry Product
• Tree Nuts
• Peanuts
• Shellfish
• Wheat
• Soys
• Other

Food Allergy Treatment Market, by Drug Type:

• Antihistamines
• Epinephrine
• Immunotherapy

Food Allergy Treatment Market, by Route of Administration:

• Oral
• Parenteral
• Other

Food Allergy Treatment Market, by End User:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Food Allergy Treatment Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Food Allergy Treatment Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.